A team reported in Nature Biotechnology the design of an engineered UGA suppressor tRNA gene intended to extend the scope of AAV‑delivered therapeutics by enabling suppression of UGA stop codons across different disease contexts. The suppressor tRNA aims to create a disease‑agnostic payload platform compatible with AAV vectors, potentially increasing the addressable patient population for certain genetic interventions. The paper describes engineering strategies to tune tRNA function in vivo and addresses delivery‑related constraints relevant to AAV cargo size and host expression. The authors framed the suppressor tRNA as a modular tool for rescue of loss‑of‑function alleles and for enabling broader use of stop‑codon suppression without gene‑specific redesign. This work is relevant to gene‑therapy developers and vector engineers because it promises a reusable genetic element that could simplify construct design and expand therapeutic reach—while also raising immunogenicity and off‑target readthrough considerations for safety assessment.